<SEC-DOCUMENT>0001193125-24-231567.txt : 20241003
<SEC-HEADER>0001193125-24-231567.hdr.sgml : 20241003
<ACCEPTANCE-DATETIME>20241003060656
ACCESSION NUMBER:		0001193125-24-231567
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241003
FILED AS OF DATE:		20241003
DATE AS OF CHANGE:		20241003

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241349760

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d893298d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as October 3, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d893298dex991.htm">Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October 3, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d893298dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g893298dsp1aa.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Completes Patient Enrolment in Randomised Phase II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> Trial in Metastatic Breast Cancer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; October 03, 2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a
clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces patient enrolment has been completed in the randomised Phase II portion of the <FONT
STYLE="white-space:nowrap">AIPAC-003</FONT> (<B>A</B>ctive <B>I</B>mmunotherapy and <B>PAC</B>litaxel) clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase II enrolled 65
metastatic hormone receptor positive (HR+), HER2-negative/low or triple-negative breast cancer patients who exhausted endocrine therapy including cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Patients across 22 clinical sites in Europe and the
United States have been randomised 1:1 to receive either 30mg or 90mg dosing of eftilagimod alpha (&#147;efti&#148;) in combination with paclitaxel to determine the optimal biological dose consistent with the FDA&#146;s Project Optimus initiative.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further updates will be provided after data collection, data cleaning,&nbsp;and analysis. For more information on the trial, please visit
clinicaltrials.gov (NCT05747794). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>catherine.strong@sodali.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the CEO of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George
Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g893298dsp1aa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893298dsp1aa.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-N^0<(2;>5@V\K'WG\"?']Y\1_@W::UJC^;K%C;ZIH>K2X"M<7>G0_N;F10
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M8?\ (TI_]>_U/J?PK_R1K2O^Q"C_ /3.:]2A_P B_P"7Z(^VP'_(DPW^!?\
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:!=S#!88;:W\(HV#8^A: "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
